According to Zhito Finance APP, ASCLETIS-B (01672) rose over 4%, as of the time of writing, it increased by 4.44%, reaching HKD 3.06, with a transaction volume of HKD 357 million.

In terms of news, ASCLETIS recently announced that its novel candidate drug ASC47 for treating obesity, used in combination with semaglutide, showed encouraging efficacy in studies using diet-induced obesity (DIO) mouse models. ASC47 is a fat-targeting drug independently developed by ASCLETIS, which has unique differentiated properties that allow it to target fat, producing dose-dependent high drug concentrations in adipose tissue, with the potential to become a first-in-class candidate drug for weight loss without muscle loss. It is reported that ASC47 is currently undergoing clinical trials in Australia for patients with obesity, and the top-line data from the Phase IIa study is expected to be released in the second quarter of 2025.

Everbright Securities stated that ASCLETIS is actively laying out in the MASH and weight loss sectors, with progress being among the best in the country. Guoyuan International also mentioned that with the clinical data from ASCLETIS expected to be released in the second quarter of 2025, the ASC30 clinical trials in the USA are smoothly underway, making the use of the company's products more convenient with vast potential. Furthermore, the company has repurchased over HKD 0.18 billion since June 2023. As of June 30, the company had approximately RMB 2.1 billion in available cash, sufficient to support R&D investment needs for over five years. The bank believes the company's value is severely underestimated and suggests keeping a close watch.